Rifaximine versus neomycin in the treatment of portosystemic encephalopathy.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  The Italian journal of gastroenterology

• Publication date

  1991-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 1742538
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Progress in the treatment of portal-systemic encephalopathy (PSE).

  1987cited by this paper
• The mechanism of hepatic coma

  1981cited by this paper
• Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy

  1977cited by this paper
• Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.

  1977cited by this paper

• Aminoglycosides, vancomycin, and metronidazole for people with cirrhosis and hepatic encephalopathy.

  2026cites this paper
• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.

  2023cites this paper
• Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?

  2020cites this paper
• New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases.

  2018cites this paper
• Mechanistic insight, diagnosis, and treatment of ammonia‐induced hepatic encephalopathy

  2018cites this paper
• STUDY TO KNOW RECURRENCE OF CLINICALLY OVERT HEPATIC ENCEPHALOPATHY IN PATIENTS WITH LIVER CIRRHOSIS, RIFAXIMIN IN CONTRAST WITH PLACEBO

  2018cites this paper
• COMPARISON OF RIFAXIMIN, LACTULOSE WITH RIFAXIMIN, LACTULOSE, BRANCHED CHAIN AMINOACIDS (BCAA) IN GRADE 1 TO GRADE 3 OF HEPATIC ENCEPHALOPATHY- NON RANDOMIZED CONTROLLED TRIAL STUDY

  2017cites this paper
• Medical Management of Portal Hypertension and Its Complications

  2017cites this paper
• Antibiotics for hepatic encephalopathy

  2017cites this paper
• Hepatic encephalopathy: pathogenesis, clinical presentation, diagnostics, treatment

  2016cites this paper
• Overview on Current Management of Hepatic Encephalopathy

  2016cites this paper
• Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis

  2016influential citation
• Systematic review with network meta‐analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy

  2015cites this paper
• Managing complications in cirrhotic patients

  2015cites this paper
• Management of overt hepatic encephalopathy.

  2015cites this paper
• Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

  2015cites this paper
• Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy

  2014cites this paper
• Efficacy and tolerability of rifaximin in combination with lactulose in end-stage liver disease patients with MELD greater than 20: a single center experience.

  2014cites this paper
• Hepatic Encephalopathy: From the Pathogenesis to the New Treatments

  2014cites this paper
• Recurrent infections and use of antibiotics Higher rates of rifaximin use in patients with recurrent infections

  2014cites this paper
• Evaluation of rifaximin in Egyptian patients with hepatic encephalopathy

  2013cites this paper
• Update on Management of Patients With Overt Hepatic Encephalopathy

  2013cites this paper
• Hepatic Encephalopathy: A Paradigm Shift

  2013cites this paper
• [Role of rifaximin in the treatment of colonic diverticular disease].

  2012cites this paper
• Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.

  2012cites this paper
• Combination Therapy for the Treatment and Prevention of Hepatic Encephalopathy

  2012cites this paper
• Pharmacotherapy for Hepatic encephalopathy: view of Evidence-Based Medicine

  2012cites this paper
• Improving Survival in Patients with Decompensated Cirrhosis

  2011influential citation
• [Rifaximin--a non-resorbable antibiotic with many indications in gastroenterology].

  2011cites this paper
• Pharmacotherapy for Hepatic encephalopathy: view of Evidence-Based

  2011cites this paper
• Management of Hepatic Encephalopathy

  2011cites this paper
• Rifaximin in the treatment of hepatic encephalopathy

  2011cites this paper
• Rifaximin – ein nicht resorbierbares Antibiotikum mit vielfältigen Anwendungsmöglichkeiten in der Gastroenterologie

  2011cites this paper
• Hepatic encephalopathy: the role of inflammation, ammonia andaquaporin expression in the pathogenesis of cerebral oedema

  2010cites this paper
• Rifaximin zur Behandlung der hepatischen Enzephalopathie

  2010cites this paper
• Treatment Options for Hepatic Encephalopathy

  2010cites this paper
• Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections

  2010cites this paper
• A rifaximina no tratamento da encefalopatia hepática

  2010cites this paper
• Rifaximin treatment in hepatic encephalopathy.

  2010cites this paper
• Rifaximin for the treatment of hepatic encephalopathy

  2010cites this paper
• Considerations on the Impact of Hepatic Encephalopathy Treatments in the Pretransplant Setting

  2010cites this paper
• Rifaximin for Treatment of Hepatic Encephalopathy

  2009cites this paper
• Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis

  2008cites this paper
• Emerging Therapies for the Management of Hepatic Encephalopathy

  2007cites this paper
• The cost‐effectiveness and budget impact of competing therapies in hepatic encephalopathy – a decision analysis

  2007cites this paper
• Review article: the current pharmacological therapies for hepatic encephalopathy

  2007cites this paper
• An algorithm for the management of hepatic encephalopathy

  2007cites this paper
• An Algorithm for the Management of Hepatic Encephalopathy

  2007cites this paper
• Management of Hepatic Encephalopathy: Focus on Antibiotic Therapy

  2006cites this paper
• Utility of the Nonabsorbed (<0.4%) Antibiotic Rifaximin in Gastroenterology and Hepatology.

  2006cites this paper
• Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.

  2006cites this paper
• Management of Hepatic Encephalopathy: Role of Rifaximin

  2005cites this paper
• Management of Diverticular Disease: Is There Room for Rifaximin?

  2005cites this paper
• Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study

  2005cites this paper
• Rifaximin: a novel antimicrobial for enteric infections

  2005cites this paper
• Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

  2003cites this paper
• Hepatic encephalopathy

  2001cites this paper
• Effects of daily oral administration of rifaximin and neomycin on faecal aerobic flora in rats.

  2001cites this paper
• Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double‐blind, randomized, dose‐finding multi‐centre study

  2000cites this paper
• An open, controlled study of two non-absorbable antibiotics for the oral treatment of paediatric infectious diarrhoea.

  1997cites this paper
• Portal systemic encephalopathy.

  1997cites this paper
• Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

  1995cites this paper
• Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double‐blind placebo‐controlled trial

  1995cites this paper
• Pharmacokinetic study of rifaximin after oral administration in healthy volunteers.

  1994cites this paper
• Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

  1993cites this paper
• Double-blind, double-dummy L. Bucci, M.D., comparison between treatment and with rifaximin and lactulose in

  1993cites this paper
• Rifaximin in the treatment of chronic hepatic encephalopathy.

  1993cites this paper
• Treatment of hepatic encephalopathy with non-absorbable antibiotics.

  1992cites this paper
• New trends in non-absorbable antibiotics in gastrointestinal disease.

  1992cites this paper
• Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group.

  1992cites this paper